Antineoplastic Agents
Patent Dispute Erupts Over Merck’s Injectable Keytruda
Merck, Halozyme, Keytruda, patent dispute, injectable cancer drug, enzyme technology
FDA Issues Untitled Letter to NJ Drugmaker for Misleading Cancer Drug Claims at Conference
FDA, untitled letter, misleading promotion, exhibit booth, cancer drug, Edenbridge Pharmaceuticals
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer, Bolstering Cancer Drug Development Efforts
Pfizer, Jeffrey Legos, oncology, cancer drug development, pharmaceutical industry, Novartis, leadership appointment
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo
Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff
Nuvation Bio Unveils Groundbreaking Cancer Drug Data from AnHeart Acquisition in China
Nuvation Bio, AnHeart, cancer drug, pivotal data, China, acquisition, clinical trials
Revitalizing Cancer Therapy: UK Biotech Acquires Kyowa Kirin’s Former Drug for Epstein-Barr-Related Diseases
UK Biotech, Kyowa Kirin, cancer drug, Epstein-Barr virus, EBV-driven diseases, drug acquisition, therapy revival.
FDA Revokes Accelerated Approval of Helsinn’s Cancer Drug at Company’s Request
FDA, Helsinn, accelerated approval, cancer drug, company request, drug withdrawal, regulatory decision, clinical trials, patient safety.